| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
IC50: 2.8 nM (Glucocorticoid receptor)[1]
Glucocorticoid receptor agonist-1 targets the glucocorticoid receptor (GR), functioning as a potent and specific agonist. It exhibits an IC₅₀ of 2.8 nM for the glucocorticoid receptor. By binding to and activating the glucocorticoid receptor, the compound modulates the transcription of glucocorticoid-responsive genes involved in inflammation, immune responses, metabolism, and various other physiological processes. The receptor is a nuclear receptor that, upon ligand binding, translocates to the nucleus and regulates gene expression. This compound's high potency makes it a valuable tool for studying glucocorticoid receptor biology. |
|---|---|
| ln Vitro |
In order to treat autoimmune diseases like rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult and pediatric Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitis, Behcets disease, a spondyloarthropathy, or psoriasis, glucose-agonist immunoconjugates bind to the glucose receptor.
In vitro, glucocorticoid receptor agonist-1 demonstrates potent agonist activity with an IC₅₀ of 2.8 nM. The compound activates glucocorticoid receptor-mediated transcription, as assessed using reporter gene assays with glucocorticoid response element (GRE)-luciferase constructs. It modulates the expression of glucocorticoid-responsive genes involved in inflammation and immune responses. The compound shows high specificity for the glucocorticoid receptor, making it a valuable tool for studying GR-mediated signaling pathways without off-target effects. Its activity is typically compared to that of dexamethasone and other glucocorticoid receptor agonists. |
| ln Vivo |
Specific in vivo activity data for glucocorticoid receptor agonist-1 are not extensively documented in the publicly available literature. As a potent glucocorticoid receptor agonist, the compound would be expected to exert anti-inflammatory and immunosuppressive effects in vivo, similar to other glucocorticoids. It may be investigated in animal models of inflammatory and autoimmune diseases. However, detailed in vivo pharmacological studies have not been published. Further research is needed to characterize its in vivo efficacy, pharmacokinetics, and safety profile. The compound is extracted from patent WO2017210471A1.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for glucocorticoid receptor agonist-1 typically involve competitive binding experiments using glucocorticoid receptor and radiolabeled or fluorescently labeled dexamethasone as tracer. The compound's binding affinity to the receptor is assessed, with an IC₅₀ of 2.8 nM determined through dose-response binding experiments. Assays are conducted in buffered solutions at physiological pH with appropriate receptor preparations. Binding affinity is expressed as IC₅₀ or Kd values. The compound's agonist activity is confirmed through functional assays measuring GRE-mediated transcriptional activation.
|
| Cell Assay |
In vitro cell-based assays for glucocorticoid receptor agonist-1 utilize cell lines expressing glucocorticoid receptor to assess its agonist activity. Cells are treated with varying concentrations of the compound for 24-48 hours. Glucocorticoid receptor-mediated transcriptional activity is evaluated using reporter gene assays with GRE-luciferase constructs. Anti-inflammatory activity is assessed by measuring the production of pro-inflammatory cytokines such as IL-6, TNF-α, and IL-1β in immune cells following stimulation. Standard cell culture conditions (37°C, 5% CO₂) with appropriate media are employed. Dose-response curves are generated to determine EC₅₀ and IC₅₀ values.
|
| Animal Protocol |
In vivo animal studies with glucocorticoid receptor agonist-1 would typically involve administration of the compound to rodent models of inflammatory or autoimmune diseases. Potential study designs include models of rheumatoid arthritis, asthma, inflammatory bowel disease, or contact hypersensitivity. Typical endpoints would include measurements of inflammation markers, assessment of tissue pathology, evaluation of immune cell infiltration, and pharmacokinetic profiling. All procedures must comply with institutional animal care and use guidelines. Detailed published in vivo protocols are not currently available.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for glucocorticoid receptor agonist-1 are not extensively documented in the publicly available literature. The compound has a molecular weight of 569.69 g/mol and a molecular formula of C₃₅H₃₉NO₆. It is typically stored at 4°C, protected from light. As a small molecule with reasonable physicochemical properties, it may have suitable characteristics for oral bioavailability, though detailed PK parameters have not been published. Further studies are needed to characterize its absorption, distribution, metabolism, and excretion profile. Standard laboratory practices should be followed for storage and handling.
|
| Toxicity/Toxicokinetics |
Glucocorticoid receptor agonist-1 is intended for research use only and is not approved for human therapeutic applications. As a research chemical, comprehensive toxicological data are not available in the publicly accessible literature. Standard safety precautions should be observed when handling this compound, including the use of appropriate personal protective equipment. As with all research chemicals, comprehensive toxicological profiling would be required before any consideration for clinical development. The compound should be handled in well-ventilated areas with proper waste disposal procedures.
|
| References | |
| Additional Infomation |
Glucocorticoid receptor agonist-1 (CAS#: 2166375-82-0) has a molecular formula of C₃₅H₃₉NO₆ and a molecular weight of 569.69 g/mol. It is a potent glucocorticoid receptor agonist with an IC₅₀ of 2.8 nM. The compound is extracted from patent WO2017210471A1 as compound 41. It modulates the glucocorticoid receptor, influencing inflammation and immune responses. This compound is not a drug and has not undergone clinical trials for therapeutic use. It is strictly a research reagent for studying glucocorticoid receptor biology and related pathways.
|
| Molecular Formula |
C35H39NO6
|
|---|---|
| Molecular Weight |
569.6873
|
| Exact Mass |
569.277
|
| CAS # |
2166375-82-0
|
| PubChem CID |
134491939
|
| Appearance |
White to off-white solid powder
|
| LogP |
4
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
42
|
| Complexity |
1160
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
O1[C@]([H])(C2C([H])=C([H])C(C([H])([H])C3C([H])=C([H])C([H])=C(C=3[H])N([H])[H])=C([H])C=2[H])O[C@]2([H])C([H])([H])[C@@]3([H])[C@]4([H])C([H])([H])C([H])([H])C5=C([H])C(C([H])=C([H])[C@]5(C([H])([H])[H])[C@@]4([H])[C@]([H])(C([H])([H])[C@]3(C([H])([H])[H])[C@]12C(C([H])([H])O[H])=O)O[H])=O
|
| InChi Key |
MPEPSOPXQDGEHP-WWBNNTNKSA-N
|
| InChi Code |
InChI=1S/C35H39NO6/c1-33-13-12-25(38)16-23(33)10-11-26-27-17-30-35(29(40)19-37,34(27,2)18-28(39)31(26)33)42-32(41-30)22-8-6-20(7-9-22)14-21-4-3-5-24(36)15-21/h3-9,12-13,15-16,26-28,30-32,37,39H,10-11,14,17-19,36H2,1-2H3/t26-,27-,28-,30+,31+,32+,33-,34-,35+/m0/s1
|
| Chemical Name |
(1S,2S,4R,6R,8S,9S,11S,12S,13R)-6-[4-[(3-aminophenyl)methyl]phenyl]-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (175.53 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.39 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7553 mL | 8.7767 mL | 17.5534 mL | |
| 5 mM | 0.3511 mL | 1.7553 mL | 3.5107 mL | |
| 10 mM | 0.1755 mL | 0.8777 mL | 1.7553 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
